Doheny Asset Management /Ca Halozyme Therapeutics, Inc. Transaction History

Doheny Asset Management /Ca

$146 Million
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$37.81 - $52.4 $4.67 Million - $6.47 Million	123,560 New	123,560 $6.47 Million
Q4 2023 Feb 06, 2024	SELL	$33.32 - $42.1 $53,312 - $67,360	-1,600 Reduced 6.62%	22,578 $834,000
Q3 2023 Nov 08, 2023	SELL	$36.46 - $44.03 $184,925 - $223,320	-5,072 Reduced 17.34%	24,178 $924,000
Q2 2023 Aug 08, 2023	SELL	$30.28 - $38.74 $827,128 - $1.06 Million	-27,316 Reduced 48.29%	29,250 $1.06 Million
Q1 2023 May 16, 2023	BUY	$32.86 - $55.7 $345,555 - $585,741	10,516 Added 22.84%	56,566 $2.16 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $463,333 - $687,483	-11,566 Reduced 20.07%	46,050 $2.62 Million
Q3 2022 Nov 10, 2022	SELL	$38.53 - $51.78 $83,802 - $112,621	-2,175 Reduced 3.64%	57,616 $2.28 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $78,965 - $101,418	-2,470 Reduced 3.97%	59,791 $2.38 Million
Q4 2021 Feb 15, 2022	SELL	$31.82 - $40.75 $577,182 - $739,164	-18,139 Reduced 22.56%	62,261 $2.5 Million
Q3 2021 Oct 22, 2021	SELL	$38.47 - $46.42 $443,559 - $535,222	-11,530 Reduced 12.54%	80,400 $3.27 Million
Q2 2021 Aug 10, 2021	SELL	$38.84 - $51.31 $1.09 Million - $1.44 Million	-28,098 Reduced 23.41%	91,930 $4.18 Million
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $100,829 - $131,300	-2,552 Reduced 2.08%	120,028 $5 Million
Q4 2020 Feb 26, 2021	SELL	$25.81 - $43.62 $116,919 - $197,598	-4,530 Reduced 3.56%	122,580 $5.24 Million
Q3 2020 Nov 12, 2020	BUY	$25.74 - $29.63 $92,664 - $106,668	3,600 Added 2.91%	127,110 $2.25 Million
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $1,287 - $1,481	-50 Reduced 0.04%	123,510 $3.25 Million
Q2 2020 Aug 18, 2020	SELL	$16.25 - $26.81 $57,687 - $95,175	-3,550 Reduced 2.79%	123,560 $3.31 Million
Q4 2019 Feb 11, 2020	BUY	$14.93 - $19.53 $161,393 - $211,119	10,810 Added 9.29%	127,110 $2.25 Million
Q3 2019 Nov 15, 2019	SELL	$15.2 - $17.69 $106,400 - $123,830	-7,000 Reduced 5.68%	116,300 $1.8 Million
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $335,857 - $393,010	-22,770 Reduced 15.59%	123,300 $2.12 Million
Q1 2019 May 14, 2019	SELL	$13.94 - $17.58 $1.13 Million - $1.43 Million	-81,123 Reduced 35.71%	146,070 $2.35 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $1.37 Million - $1.92 Million	102,800 Added 82.64%	227,193 $3.32 Million
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $401,771 - $443,441	-24,087 Reduced 16.22%	124,393 $2.26 Million
Q2 2018 Aug 10, 2018	SELL	$16.87 - $20.3 $247,482 - $297,801	-14,670 Reduced 8.99%	148,480 $2.51 Million
Q1 2018 May 17, 2018	BUY	$17.06 - $21.2 $944,270 - $1.17 Million	55,350 Added 51.35%	163,150 $3.2 Million
Q4 2017 Feb 15, 2018	SELL	$16.75 - $20.8 $1.78 Million - $2.21 Million	-106,150 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$11.76 - $17.4 $1.25 Million - $1.85 Million	106,150	106,150 $1.84 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$838 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$613 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$315 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$193 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$162 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

News

Stay updated on Doheny Asset Management /Ca with notifications on news.

Account